U.S. markets closed
  • S&P 500

    +31.63 (+0.77%)
  • Dow 30

    +297.03 (+0.89%)
  • Nasdaq

    +70.88 (+0.51%)
  • Russell 2000

    +0.88 (+0.04%)
  • Crude Oil

    -0.26 (-0.44%)
  • Gold

    -14.10 (-0.80%)
  • Silver

    -0.26 (-1.02%)

    -0.0016 (-0.13%)
  • 10-Yr Bond

    +0.0340 (+2.08%)

    -0.0029 (-0.21%)

    +0.3860 (+0.35%)

    +1,168.32 (+1.98%)
  • CMC Crypto 200

    +8.34 (+0.68%)
  • FTSE 100

    -26.47 (-0.38%)
  • Nikkei 225

    +59.08 (+0.20%)

Autism, ADHD, Asperger's Syndrome, Brain & Nervous System, Behavioral issues, Mental Health and Rett Syndrome Helped with NOXO Topical Meds. OLFC Announces Up to 50% Discount until Dec 15, 2014

PHILADELPHIA, PA /ACCESSWIRE / November 20, 2014 / Olfactory Biosciences Corp (OLFC) is pleased to announce one month discounts on new cutting edge Next Generation Meds that use natural ingredients, advanced Olfaction and chemoreception. Applying NOXO is just rubbing a small amount of the balm to the end of your nostrils. www.noxoinfo.com

NOTICE: Discount Prices Until December 15, 2014 then all products will go back to regular price at $ 49.95.

Click on any selection will present a description, pricing and an opportunity to buy,

NOXO Sensory Balm(TM)

Offers relief hypersensitivity and Autism, ADHD, Asperger's Syndrome and Rett Syndrome.

NOXO Anxiety Relief(TM)

Less anxiety, from a natural solution. Gain more calm and control from NOXO.

NOXO Mood Boost(TM)

Makes People Feel Their Best In A Calm-Energy State and can help the Brain & Nervous System

The new NOXO products are the resulting combination of NOBEL Prize-winning science (Nobel Prize in Medicine of 2004, by Richard Axel and Linda B. Buck) related to olfactory receptors and NOXO’s advanced odorant sciences using Olfaction and chemoreception.

For more information go to http://www.noxoinfo.com

See our new Facebook pages on


Ingredients: A special proprietary formulation of Phytonutrients and Phytochemicals is taken from plants, flowers, roots and seeds. All ingredients are in a high quality White Petrolatum that complies with White Petrolatum USP requirements and FDA requirements ( 21 CFR 172.880). The specific chemical identities of the ingredients in this mixture are considered by us to be trade secrets and are withheld in accordance with the provisions of the 1910.1200 of the Code of Federal Regulations.

Each NOXO Balm Tin is 3 oz. (about 100 doses or applications)

About Olfactory Biosciences Corp.

Olfactory Biosciences Corp.'s NOXO division develops products targeting olfactory receptors in the nose for the desired effect. These topical alternative medicine wellness products can modify behavior or provide relief to common behavior challenges such as anxiety or help with weight control. http://www.noxoinfo.com/


"SafeHarbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements by the Company, statements regarding the NOXO product line,optimism related to the business, expanding ales and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of the Company's products or the need to raise additional capital. In addition, actual results could vary materially based on changes or slower growth in the indoor garden market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors listed from time to time in the Company's Securities and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.

Richard Stevenson, President
Olfactory Biosciences Corp.
333 E. Lancaster Ave. Suite 317
Wynnewood, PA 19096, USA
Phone: 484-278-1626
Website: http://www.noxoinfo.com/
E-mail: support@noxoinfo.com

SOURCE: Olfactory Biosciences Corp.